BioCentury | Jun 29, 2018
Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

...body. The company's management team includes several executives from Relypsa Inc. and Ilypsa Inc. (see "Tricida: Ilypsa...
BioCentury | Jun 28, 2018
Financial News

Tricida gains, others dip after upsized IPOs

...body. The company's management team includes several executives from Relypsa Inc. and Ilypsa Inc. (see "Tricida: Ilypsa...
BioCentury | Jun 5, 2018
Financial News

Tricida files for $150M IPO

...acid from the body. The company's management team includes several executives from Relypsa Inc. and Ilypsa Inc....
...Ltd. acquired Relypsa in 2016, giving it hyperkalemia drug Veltassa patiromer. Amgen Inc. (NASDAQ:AMGN) bought Ilypsa...
...Tricida's largest shareholder, with 37%, while Sibling Capital holds 23% and Longitude Capital owns 10%. Paul Bonanos TRC101 Ilypsa Inc. Relypsa...
BioCentury | Oct 10, 2016
Clinical News

Kiklin bixalomer regulatory update

...treat CKD patients not on dialysis with hyperphosphatemia. Astellas has exclusive, Japanese rights from Amgen’s Ilypsa Inc....
BioCentury | Aug 1, 2016
Finance

Tricida: Ilypsa 3.0?

...both are hoping Tricida is the next version of Relypsa Inc. (NASDAQ:RLYP) and its predecessor Ilypsa Inc....
...and CEO Gerrit Klaerner, who co-founded both Relypsa and Ilypsa, and was Relypsa's president and Ilypsa's...
...is Veltassa patiromer, a high-capacity, non-absorbed potassium binder marketed to treat hyperkalemia in CKD patients. Ilypsa...
BioCentury | May 30, 2016
Finance

It takes a village

...in its first fund, which closed at $65 million in the fall of 2002, included Ilypsa Inc....
...received a return of about 7x when Amgen Inc. bought chronic kidney disease (CKD) company Ilypsa...
...3x. 5AM still owns a minority stake in the CKD company, which spun out of Ilypsa...
BioCentury | Apr 18, 2016
Finance

Double-dipping

...If Relypsa is acquired, it would amount to double-dipping for 5AM. Relypsa spun out of Ilypsa Inc....
...firm according to an interview with 5AM's Andy Schwab in 2009. Amgen Inc. (NASDAQ:AMGN) acquired Ilypsa...
BioCentury | Mar 7, 2016
Clinical News

Kiklin bixalomer regulatory update

...product is a metal-free, non-absorbed polymeric phosphate-binding agent. Astellas has exclusive, Japanese rights from Amgen’s Ilypsa Inc....
BioCentury | Oct 12, 2015
Clinical News

Kiklin bixalomer regulatory update

...treat CKD patients not on dialysis with hyperphosphatemia. Astellas has exclusive, Japanese rights from Amgen’s Ilypsa Inc....
BioCentury | Oct 15, 2012
Product Development

Gut instinct

...Ilypsa Inc. to develop non-absorbed ion binding polymers to help treat renal diseases. Amgen Inc. acquired Ilypsa...
...co-founder of Ilypsa Inc. and of combinatorial chemistry company Symyx Technologies Inc. , which spun out Ilypsa...
Items per page:
1 - 10 of 46
BioCentury | Jun 29, 2018
Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

...body. The company's management team includes several executives from Relypsa Inc. and Ilypsa Inc. (see "Tricida: Ilypsa...
BioCentury | Jun 28, 2018
Financial News

Tricida gains, others dip after upsized IPOs

...body. The company's management team includes several executives from Relypsa Inc. and Ilypsa Inc. (see "Tricida: Ilypsa...
BioCentury | Jun 5, 2018
Financial News

Tricida files for $150M IPO

...acid from the body. The company's management team includes several executives from Relypsa Inc. and Ilypsa Inc....
...Ltd. acquired Relypsa in 2016, giving it hyperkalemia drug Veltassa patiromer. Amgen Inc. (NASDAQ:AMGN) bought Ilypsa...
...Tricida's largest shareholder, with 37%, while Sibling Capital holds 23% and Longitude Capital owns 10%. Paul Bonanos TRC101 Ilypsa Inc. Relypsa...
BioCentury | Oct 10, 2016
Clinical News

Kiklin bixalomer regulatory update

...treat CKD patients not on dialysis with hyperphosphatemia. Astellas has exclusive, Japanese rights from Amgen’s Ilypsa Inc....
BioCentury | Aug 1, 2016
Finance

Tricida: Ilypsa 3.0?

...both are hoping Tricida is the next version of Relypsa Inc. (NASDAQ:RLYP) and its predecessor Ilypsa Inc....
...and CEO Gerrit Klaerner, who co-founded both Relypsa and Ilypsa, and was Relypsa's president and Ilypsa's...
...is Veltassa patiromer, a high-capacity, non-absorbed potassium binder marketed to treat hyperkalemia in CKD patients. Ilypsa...
BioCentury | May 30, 2016
Finance

It takes a village

...in its first fund, which closed at $65 million in the fall of 2002, included Ilypsa Inc....
...received a return of about 7x when Amgen Inc. bought chronic kidney disease (CKD) company Ilypsa...
...3x. 5AM still owns a minority stake in the CKD company, which spun out of Ilypsa...
BioCentury | Apr 18, 2016
Finance

Double-dipping

...If Relypsa is acquired, it would amount to double-dipping for 5AM. Relypsa spun out of Ilypsa Inc....
...firm according to an interview with 5AM's Andy Schwab in 2009. Amgen Inc. (NASDAQ:AMGN) acquired Ilypsa...
BioCentury | Mar 7, 2016
Clinical News

Kiklin bixalomer regulatory update

...product is a metal-free, non-absorbed polymeric phosphate-binding agent. Astellas has exclusive, Japanese rights from Amgen’s Ilypsa Inc....
BioCentury | Oct 12, 2015
Clinical News

Kiklin bixalomer regulatory update

...treat CKD patients not on dialysis with hyperphosphatemia. Astellas has exclusive, Japanese rights from Amgen’s Ilypsa Inc....
BioCentury | Oct 15, 2012
Product Development

Gut instinct

...Ilypsa Inc. to develop non-absorbed ion binding polymers to help treat renal diseases. Amgen Inc. acquired Ilypsa...
...co-founder of Ilypsa Inc. and of combinatorial chemistry company Symyx Technologies Inc. , which spun out Ilypsa...
Items per page:
1 - 10 of 46